PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

While Pfizer's dividend yield is clearly much higher than Merck's, both have relatively attractive yields today. And you ...

The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...

A direct-to-consumer program for its drugs could bring down higher U.S. drug prices while cutting out pharmacy benefit managers.

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...

Depo-Provera is a birth control shot that is injected every three months and features a type of progestin hormone called ...